Results 101 to 110 of about 8,040,892 (242)

A study of substrate removal in a microbial film reactor [PDF]

open access: yes, 1975
Includes bibliographical references.A mathematical model is formulated describing the mechanism of substrate removal by a microbial slime over which a film of liquid, containing the substrate as dissolved biodegradable material, is flowing. It is assumed
Harris, Nicholas Paul
core   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

open access: yesMolecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault   +12 more
wiley   +1 more source

Load-Dependent Nanoscale Material Removal Behaviors of β-Ga2O3(100) Surface in Single-Point Diamond Scratching: From Plastic Plowing to Brittle Fracture

open access: yesCrystals
This study investigates nanoscale material removal behavior and its correlation with subsurface damage of (100)-oriented β-Ga2O3 subjected to single-point diamond scratching across a range of normal loads.
Yanqiang Lu   +4 more
doaj   +1 more source

Removal of iodides and bromides at parts per million concentrations using a novel bismuth composite material

open access: yes, 2020
Iodide and bromide ions in surface and ground waters (typically less than 0.05 mg/L for iodide and 0.5 mg/L for bromide) could react with natural organic matters under oxidative disinfection process and produce toxic disinfectant by-products.
Nariyan, E   +7 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Advances in Multi-Level Compensation Strategy and Process Collaborative Optimization for Robotic Belt Grinding

open access: yesTechnologies
Robotic belt grinding is an effective and widely adopted finishing method for superalloys, offering notable advantages such as high material removal capability, low heat input, and reduced workpiece damage.
Zhuoshi Li   +3 more
doaj   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

open access: yesMolecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim   +11 more
wiley   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy